Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Aquestive Therapeutics Inc.

Aquestive Therapeutics (AQST) called Anaphylm a breakthrough and told investors approval was on track. The company also signaled the allergy treatm...

Aquestive Therapeutics Faces Investor Lawsuit Over Alleged Misleading Statements About Anaphylm FDA Approval Timeline 

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aquestive Therapeutics (AQST) and Insmed (INSM) with...

Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Insmed (INSM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alumis Inc. (ALMS) and Aquestive Therapeutics (AQST)...

Analysts Are Bullish on These Healthcare Stocks: Alumis Inc. (ALMS), Aquestive Therapeutics (AQST)

Aquestive Therapeutics ( ($AQST) ) just unveiled an announcement. On March 16, 2026, Aquestive Therapeutics agreed that longtime Chief Legal Office...

Aquestive Therapeutics Announces Key Legal Leadership Transition

Aquestive Therapeutics ($AQST) promoted Anaphylm to investors as a device-free, orally delivered epinephrine film intended for severe allergic reac...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AQST	$4.17	+0.85%	1.06M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AQST	$4.17	+0.8%	1.06M
3
4
5
6

AQST

AQST

No Data Available

Get Aquestive Therapeutics Inc. Data in Excel

Get Aquestive Therapeutics Inc. Data in Excel